



## Zeltia Announces Delay in Reimbursement Price Agreements for Yondelis<sup>®</sup> in Some European Territories

**Madrid, Spain 21<sup>st</sup> September 2010:** Zeltia S.A. (ZEL.MC) ('Zeltia' or 'the Company'), Spain's largest biopharmaceutical company, today announces that due to delays in obtaining reimbursement price agreements from the health authorities of England (NICE), Scotland, France, Netherlands, Belgium and Portugal for Yondelis<sup>®</sup> in ovarian cancer, as well as an important price cut in Spain, sales of the product for that indication will be lower than expected for the financial year 2010.

As a consequence of the aforementioned delays in obtaining reimbursement price agreements, the Company estimates sales for the biopharmaceutical segment to be around 15%-30% below the forecast published on 3<sup>rd</sup> March 2010. However, the Company expects the biopharmaceutical sector sales to be 70% higher than those obtained in 2009.

At the Group level, this revision means that consolidated sales will be 10%-20% below the last forecast published in March 2010, however, Zeltia expects a growth of consolidated sales of around 30% compared to the full year of 2009.

### **About Zeltia:**

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. The main Grupo Zeltia are: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

**For more information, contact Zeltia at +34 91 444 4500.**